STA-363 is under clinical development by Stayble Therapeutics and currently in Phase II for Chronic Low Back Pain (CLBP). According to GlobalData, Phase II drugs for Chronic Low Back Pain (CLBP) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STA-363’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STA-363 overview
STA-363 is under development for the treatment of discoid chronic low back pain and chronic disc herniation (LDH). It is administered as intradiscal injection. Drug candidate comprises of small molecule together with a contrast agent to guide the correct placement of the injection into the centre of the intervertebral disc space.
It was also under development for the treatment of degenerative disc disease (DDD).
Stayble Therapeutics overview
Stayble Therapeutics (Stayble) is a pharmaceutical company. It develops injection-based treatment against chronic low back pain (cLBP) triggered by damage in the disc. The company offers products that includes invasive injection based treatment for the removal of pain and the need of spinal fusion in patients suffering from cLBP. Stayble offers injection treatment for transforming the disc centre from being a liquid into solid state. It caters to surgeons, hospitals and patients. Stayble is headquartered in Gothenburg, Sweden.
For a complete picture of STA-363’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
